Guardant Health (GH) PT Raised to $70 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts GH Hot Sheet
Price: $185.31 +1.49%
Rating Summary:
30 Buy, 1 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
30 Buy, 1 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
Barclays analyst Luke Sergott raised the price target on Guardant Health (NASDAQ: GH) to $70.00 (from $60.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Guardant Health (GH) PT Raised to $210 at BTIG, remains Top Pick
- Bausch Health Companies (BHC) PT Raised to $8 at Jefferies
- Kymera Therapeutics (KYMR) PT Raised to $140 at Oppenheimer
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
